About Midatech Ltd/
the Midatech Group
Midatech is at the forefront of designing, developing, synthesizing and manufacturing nanomedicines based on its proprietary, self assembling biocompatible nanoparticle technology.
The company has successfully employed its nanotechnology platform and know-how to transition discovery and engineering sciences to practical nanomedicine applications through in-house and partnered drug development programs. Midatech’s unique nanoparticles allow rapid targeting of drugs or drug combinations to specific tissues or cells as well as potentially enabling transport across the blood brain barrier.
Midatech’s mission is to become the global leader and centre of competence in the nanomedicine arena.
Midatech is a privately-owned Group of Companies with a strong patent estate.
News
05 Jan 2012 – MonoSol Rx and Midatech Launch MidaSol Therapeutics LP (PDF, 197 kB)
05 Jan 2012 – Midatech Secures £6.3 Million Financing to Strengthen Product Development Portfolio (PDF, 212 kB)
15 Nov 2011 – Midatech receives Regulatory Approval for Clinically Testing Ultra-small Gold Nanoparticles (PDF, 153 kB)
01 Jun 2011 – Midatech Receives Manufacturing License in Spain for its Nanoparticles (PDF, 130 kB)
04 Jan 2011 – MonoSol Rx and Midatech Ltd Complete Transbuccal Insulin Delivery Study in Primate Diabetes Model (PDF, 199 kB)
08 Dec 2010 – MonoSol Rx and Midatech to Develop Insulin in PharmFilm®; To Establish Joint Venture. (PDF, 166 kB)
17 Aug 2010 – Midatech and Monosol Rx Announce Filing of Joint Patent Application for Nanoparticle Film Delivery Systems. (PDF, 159 kB)
12 Jul 2010 – Midatech and Immunotope Form Joint Venture, Syntara LLC, for the Development of Immune Therapies. (PDF, 184 kB)
24 Jun 2010 – Midatech Expands Collaboration with Monosol Rx to Deliver Peptides Utilizing Nanotechnology and PharmFilm® Drug Delivery Technology. (PDF, 158 kB)
15 Jun 2010 – Midatech Announces Research and Development Collaboration with Mayo Clinic. (PDF, 112 kB)
05 Dec 2008 – Midatech Announces Positive Proof-of-Mechanism Results from £1.5 million Antibiotic Nanoparticle Study. (PDF, 74 kB)
Events
SACHS European Life Science CEO Forum for Partnering & Investing
March 6 – March 7, 2012, Zurich, Switzerland: attendance and presentation has been confirmed
5th European CLINAM conference for clinical nanomedicine
May 7 – May 9, 2012, Basel, Switzerland: attendance and presentation has been confirmed
